NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical показать больше
trial to treat patients with moderate coronavirus disease (COVID-19) NB-01 for the treatment of painful diabetic neuropathy NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19) NB-01 for the treatment of painful diabetic neuropathy NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.
– моментальные уведомления о рынке акций
